Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Data suggest genital screening misses many STI cases in women
    STI Quarterly

    Data suggest genital screening misses many STI cases in women

    September 1, 2015
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Data Suggest Hormonal Therapy Doesn’t Increase VTE Risk in Women on Anticoagulant Therapy

    Fewer cases, but sicker? Data suggest it’s true

    Genital wart cases drop after program launched

    Related Products

    Glucose Screening: The Meaning of a Single Abnormal Value in a 3-hour Glucose Tolerance Test

    By Using In Vitro Fertilization, Pregnancy Rates Can Approach Those in Fertile Women

    Executive Summary

    Data from a recent study that looked at more than 10,000 people who attended a Baltimore public health clinic indicate the occurrence of gonorrhea or chlamydia in extragenital areas such as the throat or rectum is significant in women, particularly younger women.

    • Current public health guidelines call for routine screening for extragenital gonorrhea and chlamydia in men who have sex with men and people with HIV, given the high burden of these sexually transmitted infections in these at-risk populations.
    • However, there are no current recommendations to routinely screen women at extragenital sites.

    Data from a recent study that looked at more than 10,000 people who attended a Baltimore public health clinic indicate the occurrence of gonorrhea or chlamydia in extragenital areas such as the throat or rectum is significant in women, particularly younger women.1

    Researchers from Johns Hopkins University School of Medicine in Baltimore looked at health records from 10,389 people (4,402 women, 5,218 heterosexual men, and 769 men who have sex with men [MSM]) who visited the Baltimore City Health Department Eastern Health District or the Druid STD Clinic between June 2011 and May 2013. All of the people included in the study had reported recent exposure to oral and/or anal sexual intercourse.

    Current public health guidelines call for routine screening for extragenital gonorrhea and chlamydia in MSM and people with HIV, given the high burden of these sexually transmitted infections (STIs) in these at-risk populations. However, there are no current recommendations to routinely screen women at extragenital sites.

    When infections from gonorrhea and chlamydia occur in extragenital areas, they are typically asymptomatic, said Joshua Trebach, a third-year student at the Johns Hopkins University School of Medicine in a press statement accompanying the research publication. “These types of infections pose a large and hidden public health threat, because they can be transmitted to unwitting sexual partners and form an active infection,” he noted.

    Screening cost-effective?

    If the women examined in the Johns Hopkins University study had received only genital STI tests, nearly 14% of chlamydia infections and more than 30% of gonorrhea infections would have been missed. Researchers found the total prevalence of extragenital gonorrhea or chlamydia among the more than 4,000 women screened was 2.4% and 3.7%, respectively. By comparison, the extragenital rates for MSM were 18.9% for gonorrhea and 11.8% for chlamydia.

    While the prevalence of extragenital gonorrhea and chlamydia is highest in MSM, a significant number of gonorrhea and chlamydia infections in young women would be missed with genital-only testing, researchers note. Cost-effectiveness analyses are needed to help inform national guidelines on extragenital screening in young women, they state.

    To understand the cost effectiveness of screening women for extragenital infections, first there needs to be an understanding of how such infections impact reproductive health in women, says one of the research paper co-authors, Khalil Ghanem, MD, PhD, associate professor of medicine at the University. By not detecting and treating these infections, what is the impact on the likelihood of transmission to male partners and the probability that these male partners will transmit the infection to their female partners in the genital tract, leading to poor reproductive outcomes?

    “This seems like it would be a rare occurrence, but on a population level, it might not be so rare,” notes Ghanem.

    3 questions

    The issue goes to the questions of the role of extragenital infections in driving the prevalence of Neisseria gonorrhoeae and Chlamydia trachomatis in a population, how these infections impact HIV transmission/acquisition in women and their sexual partners, and how these infections contribute to the emergence of resistance, says Ghanem. These questions are particularly important for gonorrhea, as it is believed that pharyngeal infections are the source of many, if not most, resistant mutations.2

    “None of these questions have easy answers,” observes Ghanem. “Ideally, the next step is to try and develop models to help gauge the potential impact of extragenital infections on reproductive outcomes, HIV acquisition/transmission, and emergence of resistance.”

    Such action might be easier said than done because researchers will have to input variables in a model.” Because many of these variables are not known, and cannot be easily extrapolated from a clinical setting, such research presents “a very big challenge,” notes Ghanem.

    Screening is important

    In MSM, most of the screening benefit comes from HIV acquisition/transmission reduction that comes with extragenital screening, Ghanem comments. This reduction is why extragenital screening is recommended in this population, he notes.

    Gonorrhea and chlamydia are much more prevalent in the MSM population than in the heterosexual population. Data from a review of 42 U.S. clinics show extragenital gonorrhea and chlamydia was common among MSM attending STI clinics.3 As such, the impact is much greater and can be quantified, says Ghanem.

    “Most of the impact in women would have to come from how these infections impact reproductive health,” Ghanem states. “That’s a big unknown.”

    REFERENCES

    1. Trebach JD, Chaulk CP, Page KR, et al. Neisseria gonorrhoeae and Chlamydia trachomatis among women reporting extragenital exposures. Sex Transm Dis 2015; 42(5):233-239.
    2. Weinstock H, Workowski KA. Pharyngeal gonorrhea: An important reservoir of infection? Clin Infect Dis 2009; 49(12):1798-1800.
    3. Patton ME, Kidd S, Llata E, et al. Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men — STD Surveillance Network, United States, 2010-2012. Clin Infect Dis 2014; 58(11):1564-1570.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Contraceptive Technology Update

    View PDF
    Contraceptive Technology Update 2015-09-01
    September 1, 2015

    Table Of Contents

    Counseling on LARC methods cuts unintended pregnancy rates

    Single-size Caya diaphragm is available by prescription in U.S.

    What are the options available for medication prior to IUD placement?

    Long-acting reversible contraceptives used by few women after delivery

    Study: Obese teens less likely to use contraception

    Gay, lesbian, and bisexual youth grouped, show increased risk for unintended pregnancy

    Liletta IUD available in the United States

    Time to update your clinical practice: 2015 STD Treatment Guidelines available

    Data suggest genital screening misses many STI cases in women

    Get CDC fact sheet on shigellosis

    Begin Test

    Buy this Issue/Course

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing